Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Patient receiving sunitinib according the clinician's independent decision as first-line
treatment of advanced renal cell carcinoma (RCC) will be asked for informed consent.
Treatment with sunitinib will start and end solely on the treating clinicians and the
patients independent discretion. Consenting patients will prospectively answer standardized
quality of life questionnaires (15D, EQ-5D) during the treatment. Data on health care
resource utilisation will be collected prospectively (outpatient visits, hospital stays,
concomitant drugs, investigations, sick-leaves, travels). In addition, after treatment
failure anti-cancer drugs, hospital stays and date of death will be recorded.
The health economic data during sunitinib treatment and the length of the sunitinib treatment
will be compared with the corresponding previously published data collected retrospectively
from patients with the same condition treated with IFN-alfa. Stepwise regression analysis
will be used to explore whether patient and tumor characteristics explain potential variation
in treatment duration and costs that is not explained by the treatment.
Health-related quality of life (HRQoL) data will be presented as descriptive data and
compared to age-standardized general population.
At least four major Finnish oncology centers have consented to participate in this study. The
inclusion time will be approximately 24 months, and the study time approximately 48 months.
Eighty patients will be included.